blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4069846

EP4069846 - COMPOSITIONS AND METHODS FOR THE TARGETING OF HTT [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  09.09.2022
Database last updated on 26.07.2024
FormerThe international publication has been made
Status updated on  11.06.2021
Formerunknown
Status updated on  11.01.2021
Most recent event   Tooltip19.01.2024Change - representative 
Applicant(s)For all designated states
Scribe Therapeutics Inc.
1150 Marina Village Parkway
Alameda, CA 94501 / US
[2022/41]
Inventor(s)01 / OAKES, Benjamin
c/o Scribe Therapeutics Inc.
1150 Marina Village Parkway
Alameda, California 94501 / US
02 / HIGGINS, Sean
c/o Scribe Therapeutics Inc.
1150 Marina Village Parkway
Alameda, California 94501 / US
03 / SPINNER, Hannah
c/o Scribe Therapeutics Inc.
1150 Marina Village Parkway
Alameda, California 94501 / US
04 / DENNY, Sarah
c/o Scribe Therapeutics Inc.
1150 Marina Village Parkway
Alameda, California 94501 / US
05 / STAAHL, Brett T.
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
06 / TAYLOR, Kian
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
07 / BANEY, Katherine
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
08 / COLIN, Isabel
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
09 / ADIL, Maroof
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
10 / URNES, Cole
c/o Scribe Therapeutics Inc. 1150 Marina Village
Parkway
Alameda, California 94501 / US
 [2022/41]
Representative(s)Boanas-Evans, Duncan Richard
Eli Lilly and Company Limited
8 Arlington Square West
Downshire Way
Bracknell, Berkshire RG12 1PU / GB
[N/P]
Former [2022/41]Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
Application number, filing date20829464.504.12.2020
[2022/41]
WO2020US63484
Priority number, dateUS201962945131P07.12.2019         Original published format: US 201962945131 P
[2022/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021113769
Date:10.06.2021
Language:EN
[2021/23]
Type: A1 Application with search report 
No.:EP4069846
Date:12.10.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 10.06.2021 takes the place of the publication of the European patent application.
[2022/41]
Search report(s)International search report - published on:EP10.06.2021
ClassificationIPC:C12N15/113, C12N9/22, A61K31/7088, A61P25/14
[2022/41]
CPC:
C12N9/22 (EP,US); C12N15/113 (EP); C12N15/86 (US);
C12N2310/20 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/41]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN FÜR HTT-TARGETING[2022/41]
English:COMPOSITIONS AND METHODS FOR THE TARGETING OF HTT[2022/41]
French:COMPOSITIONS ET MÉTHODES POUR LE CIBLAGE DE HTT[2022/41]
Entry into regional phase30.06.2022National basic fee paid 
30.06.2022Designation fee(s) paid 
30.06.2022Examination fee paid 
Examination procedure30.06.2022Examination requested  [2022/41]
30.06.2022Date on which the examining division has become responsible
24.01.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
26.12.2022Renewal fee patent year 03
26.12.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2009135322  (UNIVERSTITY OF BRITISH COLUMBI, et al) [Y] 1-75,78,80-129,140-170 * example 9; claims 1,6,7,10; sequences 1,68 *;
 [A]WO2016191684  (FINER MITCHELL H [US], et al) [A] 1-75,78,80-129,140-170 * pages 23,34,35; claims 1,31-33,59-64,124-127 * * pages 37,82 *;
 [A]WO2017068077  (INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM) [FR], et al) [A] 1-75,78,80-129,140-170 * page 20 - page 22; claims 1-21 *;
 [A]WO2018064371  (UNIV CALIFORNIA [US]) [A] 1-75,78,80-129,140-170 * paragraphs [0067] , [0 68] , [0 73] - [0077] - [ 131] - [0134]; claims 1-13,70,119; sequences 1,42 *;
 [Y]WO2019191341  (FACTOR BIOSCIENCE INC [US]) [Y] 1-75,78,80-129,140-170 * page 106; example 30; claims 1,19,24,26,29,45 * * page 112 - page 113 *;
 [Y]  - ALEX MAS MONTEYS ET AL, "CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo", MOLECULAR THERAPY, (20170104), vol. 25, no. 1, doi:10.1016/j.ymthe.2016.11.010, ISSN 1525-0016, pages 12 - 23, XP055574814 [Y] 1-75,78,80-129,140-170 * page 18, column r - page 19, column l; figure 1 *

DOI:   http://dx.doi.org/10.1016/j.ymthe.2016.11.010
 [Y]  - Monteys Alex Mas ET AL, "Supplemental Information CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo", Molecular Therapy, (20170104), URL: https://ars.els-cdn.com/content/image/1-s2.0-S1525001616453931-mmc1.pdf, (20210223), XP055778983 [Y] 1-75,78,80-129,140-170 * figure 1; table 1 *
 [A]  - EKMAN FREJA K. ET AL, "CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model", MOLECULAR THERAPY: NUCLEIC ACIDS., US, (20190726), vol. 17, doi:10.1016/j.omtn.2019.07.009, ISSN 2162-2531, pages 829 - 839, XP055779039 [A] 1-75,78,80-129,140-170 * figures 1-3 *

DOI:   http://dx.doi.org/10.1016/j.omtn.2019.07.009
 [A]  - JUN WAN SHIN ET AL, "Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9", HUMAN MOLECULAR GENETICS, (20160915), doi:10.1093/hmg/ddw286, ISSN 0964-6906, page ddw286, XP055403489 [A] 1-75,78,80-129,140-170 * figures 2,3; table 1 *

DOI:   http://dx.doi.org/10.1093/hmg/ddw286
 [A]  - DABROWSKA MAGDALENA ET AL, "Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases", FRONTIERS IN NEUROSCIENCE, (20180226), vol. 12, doi:10.3389/fnins.2018.00075, XP055779041 [A] 1-75,78,80-129,140-170 * figures 1-3 *

DOI:   http://dx.doi.org/10.3389/fnins.2018.00075
by applicantUS5173414
 US5405783
 US5412087
 US5445934
 US5695937
 WO2010075303
 WO2012068627
 WO2018064371
 US2018258424
 WO2018195555
 US10570415
    - BATES, GP et al., "Huntington disease", Nat. Rev. Dis. Primers, (20150000), vol. 1, doi:10.1038/nrdp.2015.52, page 15005, XP055762301

DOI:   http://dx.doi.org/10.1038/nrdp.2015.52
    - LEE, J, "An upstream open reading frame impedes translation of the huntingtin gene", Nucleic Acids Res, (20021201), vol. 30, no. 23, page 5110
    - KOLI, N et al., "CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease", Int. J. Mol. Sci., (20170000), vol. 18, doi:10.3390/ijms18040754, page 754, XP055466760

DOI:   http://dx.doi.org/10.3390/ijms18040754
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - ZHANGMADDEN, Genome Res., (19970000), vol. 7, pages 649 - 656
    - SMITHWATERMAN, Adv. Appl. Math., (19810000), vol. 2, pages 482 - 489
    - GHIRLANDO et al., Immunol Lett, (19990000), vol. 68, pages 47 - 52
    - LIN B et al., "Structural analysis of the 5' region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di-and trinucleotide polymorphisms", Genomics, (19950000), vol. 25, no. 3, doi:10.1016/0888-7543(95)80014-D, page 707, XP004796587

DOI:   http://dx.doi.org/10.1016/0888-7543(95)80014-D
    - THOMPSON, SBLEAVITT, BR, "Transcriptional Regulation of the Huntingtin Gene", J Huntingtons Dis, (20180000), vol. 7, no. 4, page 289
    - FOUST, KD et al., "Therapeutic AAV9-mediated suppression of mutant HTT slows disease progression and extends survival in models of inherited ALS", Mol Ther, (20130000), vol. 21, no. 12, page 2148
    - CHEN et al., Pharm Res, (20030000), vol. 20, pages 1952 - 60
    - MURRAY et al., J. Chromatogr Sci, (20020000), vol. 40, pages 343 - 9
    - ZENDER et al., Cancer Gene Ther, (20020000), vol. 9, no. 6, pages 489 - 96
    - NOGUCHI et al., Diabetes, (20030000), vol. 52, no. 7, pages 1732 - 1737
    - TREHIN et al., Pharm. Research, (20040000), vol. 21, pages 1248 - 1256
    - WENDER et al., Proc. Natl. Acad. Sci. USA, (20000000), vol. 97, pages 13003 - 13008
    - AGUILERA et al., Integr Biol (Camb, (20090600), vol. 1, no. 5-6, pages 371 - 381
    - TRATSCHIN et al., Mol. Cell. Biol., (19850000), vol. 5, pages 3251 - 3260
    - TRATSCHIN et al., Mol. Cell. Biol., (19840000), vol. 4, pages 2072 - 2081
    - HERMONATMUZYCZKA, PNAS, (19840000), vol. 81, pages 6466 - 6470
    - SAMULSKI et al., J. Virol., (19890000), vol. 63, pages 03822 - 3828
    - KOTIN, R. M., Human Gene Therapy, (19940000), vol. 5, pages 793 - 801
    - "Parvoviridae and their Replication", BERNS, K. I., Fundamental Virology
    - MCDONALD, D. et al., "Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins", PLoS ONE, (20140000), vol. 9, no. 5, page e96854
 WO2020US36505
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.